Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 01 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Bariatric surgery is associated with long-term remission of type 2 diabetes

This week's Journal of the American Medical Association examines the association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.

News image

Short-term studies show that bariatric surgery causes remission of diabetes.

The long-term outcomes for remission and diabetes-related complications are not known.

Dr Lars Sjöström and colleagues determined the long-term diabetes remission rates, and the cumulative incidence of microvascular and macrovascular diabetes complications after bariatric surgery.

The Swedish Obese Subjects (SOS) is a prospective matched cohort study conducted at 25 surgical departments and 480 primary health care centers in Sweden.

Of patients recruited between 1987 and 2001, 260 of 2037 control patients and 343 of 2010 surgery patients had type 2 diabetes at baseline.

For the current analysis, diabetes status was determined at SOS health examinations until 2013.

The diabetes remission rate 2 years after surgery was 72% for bariatric surgery patients
Journal of the American Medical Association

Information on diabetes complications was obtained from national health registers until 2012.

Participation rates at the 2-, 10-, and 15-year examinations were 81%, 58%, and 41% in the control group, and 90%, 76%, and 47% in the surgery group.

For diabetes assessment, the team found that the median follow-up time was 10 years and 10 years in the control and surgery groups, respectively.

For diabetes complications, team noted that the median follow-up time was 17 years, and 18 years in the control and surgery groups, respectively.

Adjustable or nonadjustable banding, vertical banded gastroplasty, or gastric bypass procedures were performed in the surgery group, and usual obesity and diabetes care was provided to the control group.

The team's main outcome measures included diabetes remission, relapse, and diabetes complications.

Remission was defined as blood glucose <110 mg/dL and no diabetes medication.

The diabetes remission rate 2 years after surgery was 16% for control patients, and 72% for bariatric surgery patients.

At 15 years, the team noted that diabetes remission rates decreased to 7% for control patients, and to 30% for bariatric surgery patients.

With long-term follow-up, the cumulative incidence of microvascular complications was 42 per 1000 person-years for control patients, and 21 per 1000 person-years in the surgery group.

The research team observed macrovascular complications in 44 per 1000 person-years in control patients, and 32 per 1000 person-years for the surgical group.

Dr Sjöström's team comments, "In this very long-term follow-up observational study of obese patients with type 2 diabetes, bariatric surgery was associated with more frequent diabetes remission and fewer complications than usual care."

"These findings require confirmation in randomized trials."

JAMA 2014;311(22):2297-2304
12 June 2014

Go to top of page Email this page Email this page to a colleague

 01 July 2016 
Aspirin and colorectal cancer
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Acute severe ulcerative colitis
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us